Specialties – Page 55

Impact of Early Extracranial Surgery on One-Year Outcomes After Traumatic Brain Injury: Insights from the TRACK-TBI Study

By MedXY 10/21/2025

Early extracranial surgery following moderate-severe traumatic brain injury or positive CT findings is linked to worse cognitive, functional, and quality of life outcomes at one year, highlighting the need to refine surgical timing and post-injury interventions.

Neurology news Rehabilitation Medicine Specialties

Evaluating Electromagnetic Network-Targeted Field Therapy for Post-Ischemic Stroke Disability: Insights from the EMAGINE Trial

By MedXY 10/21/2025

The EMAGINE randomized clinical trial assessed low-intensity electromagnetic stimulation combined with rehabilitation in moderate to severe ischemic stroke patients. While safe, it did not yield statistically significant functional improvement, warranting further investigation.

Cardiology Family Medicine & Nutrition Specialties

Optimizing Food Insecurity Interventions to Lower Blood Pressure: Insights from the Healthy Food First Trial

By MedXY 10/21/2025

A factorial RCT in food-insecure adults with hypertension found that healthy food subsidies modestly reduced blood pressure compared with delivered food boxes, while lifestyle counseling and longer duration showed no added benefit.

AI Critical Care Emergency Medicine Pediatrics Specialties

Advancing Early Pediatric Sepsis Detection: Machine Learning Models Predicting Onset Within 48 Hours

By MedXY 10/21/2025

This study developed and validated machine learning models with high accuracy to predict early pediatric sepsis and septic shock within 48 hours using multisite electronic health record data in emergency departments.

AI General Surgery Oncology Specialties

Medicare Advantage and Cancer Surgery Outcomes: Are Patients Being Routed Away from High-Quality Hospitals?

By MedXY 10/21/2025

This retrospective national cohort study reveals that Medicare Advantage (MA) enrollees undergoing major cancer surgery are less likely to receive care at high-quality hospitals compared to traditional Medicare beneficiaries, raising concerns about MA networks' impact on access to optimal surgical care.

Clinical Updates Neurology Specialties

Transcutaneous Peripheral Nerve Stimulation for Essential Tremor: Advancements from a 2024 Randomized Clinical Trial and Evolving Evidence

By MedXY 10/21/2025

AI-driven transcutaneous peripheral nerve stimulation (TPNS) shows significant improvements in upper limb function for essential tremor (ET), supporting a promising noninvasive treatment approach with manageable safety profile over 90 days.

Oncology Specialties Urology

Impact of Enzalutamide on PSA Dynamics and Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights from the ARCHES Trial Secondary Analysis

By MedXY 10/21/2025

This secondary analysis of the ARCHES trial demonstrates that enzalutamide plus ADT improves progression-free and overall survival in mHSPC patients across PSA levels, with undetectable PSA strongly predicting favorable outcomes.

Oncology Specialties Urology

Cribriform Morphology’s Impact on Long-term Metastasis Risk in Prostate Cancer: Insights from the PROTECT Trial

By MedXY 10/21/2025

A secondary analysis of the PROTECT trial reveals cribriform-positive prostate cancer significantly elevates 15-year metastasis risk, with radiotherapy plus neoadjuvant ADT reducing this risk more effectively than surgery or active monitoring.

OB/GYN & Women's Health Oncology Radiology Specialties

Personalizing Radiotherapy in Ductal Carcinoma In Situ Using a 12-Gene Expression Assay: Insights from a Prospective Clinical Trial

By MedXY 10/21/2025

This clinical trial prospectively evaluates how a 12-gene expression assay (DCIS score) guides postoperative radiotherapy decisions after breast-conserving surgery in ductal carcinoma in situ, showing tailored radiotherapy use may reduce ipsilateral breast events.

AI Oncology Pathology & Lab Medicine Specialties

Enhancing Melanoma Prognosis: AI-Driven Quantification of Tumor-Infiltrating Lymphocytes Outperforms Traditional Pathology

By MedXY 10/21/2025

This study demonstrates that an AI algorithm provides more reproducible and prognostically relevant assessment of tumor-infiltrating lymphocytes in melanoma compared to traditional pathologist methods, offering a promising tool to improve clinical decision-making.

AI Oncology Pathology & Lab Medicine Specialties

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives

By MedXY 10/21/2025

AI-detected tumor-infiltrating lymphocytes on routine histology independently predict response and survival in advanced melanoma treated with anti-PD-1 therapies, outperforming manual scoring and offering an accessible biomarker for immune checkpoint inhibitor outcomes.

AI Oncology Respiratory Specialties

Enhancing Lung Cancer Screening Uptake Through a Direct-to-Patient Digital Health Intervention: Insights from a Randomized Clinical Trial

By MedXY 10/21/2025

A digital health program significantly increased lung cancer screening rates among high-risk individuals, underscoring digital tools' potential to improve preventive care.

患者向けデジタルヘルス介入による肺がんスクリーニング受診率の向上：ランダム化比較試験からの洞察

By MedXY 10/21/2025

デジタルヘルスプログラムは、高リスク個体の肺がんスクリーニング率を大幅に向上させ、予防医療の改善にデジタルツールの潜在力を示しています。

Cardiology news Public Health

Active Monitoring for Atrial Fibrillation (AMALFI): Advancing Long-Term Remote Screening to Reduce Stroke Risk

By MedXY 10/21/2025

The AMALFI trial evaluates remote screening for asymptomatic atrial fibrillation in older adults to improve detection, anticoagulation use, and reduce stroke risk, with findings pending follow-up at 2.5 and 5 years.

Cardiology news Public Health

Remote ECG Patch Screening for Asymptomatic Atrial Fibrillation: Insights from the AMALFI Trial

By MedXY 10/21/2025

The AMALFI trial demonstrates that remote, mail-based 14-day ECG patch screening modestly increases long-term atrial fibrillation detection and anticoagulation use in older adults at stroke risk, with no observed reduction in stroke at 2.5 years.

news Psychiatry

Azetukalner: A Novel KV7 Potassium Channel Opener Shows Promise in Treating Major Depressive Disorder

By MedXY 10/21/2025

Azetukalner, a KV7 potassium channel opener, demonstrated clinically meaningful antidepressant effects and significant improvement in anhedonia in adults with major depressive disorder in a 6-week randomized trial, supporting further development.

Internal Medicine Oncology Specialties

Evaluating Methylphenidate for Fatigue Management in Advanced Cancer: Insights from the MePFAC Randomized Controlled Trial

By MedXY 10/21/2025

The MePFAC trial demonstrates that methylphenidate is safe but does not significantly reduce fatigue compared to placebo in advanced cancer patients receiving palliative care, challenging previous assumptions about its efficacy.

Internal Medicine Psychiatry Specialties

Single-Dose MM120 (Lysergide) Shows Promise in Treating Generalized Anxiety Disorder: Phase 2b RCT Results

By MedXY 10/21/2025

A phase 2b trial reveals that single doses of MM120 produce dose-dependent reductions in anxiety symptoms in adults with moderate to severe generalized anxiety disorder, paving the way for phase 3 studies.

Cardiology Pediatrics Specialties Transplantation

Everolimus and Low-Dose Tacrolimus Therapy After Pediatric Heart Transplant: Insights from a Multicenter Randomized Clinical Trial

By MedXY 10/21/2025

This randomized trial evaluates the safety and efficacy of everolimus combined with low-dose tacrolimus versus standard immunosuppression in children 6 months post-heart transplant, highlighting comparable rejection rates, improved kidney function, and reduced CMV infection risk.

Neurology Specialties

Oral Valiltramiprosate in APOEε4/ε4 Carriers with Early Alzheimer’s Disease: Insights from the Phase III APOLLOE4 Trial

By MedXY 10/21/2025

This phase III trial evaluated oral valiltramiprosate in APOEε4/ε4 homozygotes with early Alzheimer's, showing brain atrophy slowing but limited overall clinical benefit, with nominal improvements in mild cognitive impairment subgroups.